|
A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Almac Diagnostics |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - OncoMark |
Consulting or Advisory Role - Carrick Therapeutics |
Research Funding - Carrick Therapeutics |
Patents, Royalties, Other Intellectual Property - Two patents which have been licenced to OncoMark Limited |
Travel, Accommodations, Expenses - OncoMark |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |